Hematology Frontier

A Comprehensive Review of Annual Advances and Guideline Updates, and a Look Ahead at New Trends in Clinical Practice 丨Northern Breast Cancer Salon Editor’s Note As the year turns, another…

Editor’s Note At the beginning of the new year, distinguished experts gathered in Tianjin. From January 9 to 11, 2026, the 6th China Congress on the Advancement of Hematology (CASH)…

Editor’s Note At the dawn of the new year, leading experts convened in Tianjin. From January 9 to 11, 2026, the 6th China Congress on the Advancement of Hematology (CASH)…

Editor’s Note At the beginning of the new year, leading experts gathered in Tianjin. From January 9 to 11, 2026, the 6th China Congress on the Advancement of Hematology (CASH)…

With the dawn of the new year, Tianjin once again became a hub for academic exchange. From January 9 to 11, 2026, the 6th China Annual Conference on the Development of Hematology (CASH) was grandly held in Tianjin. Bringing together leading experts in hematology from China and abroad, the conference focused on disciplinary frontiers and national health strategies, fostering in-depth discussions on the latest research advances and future directions.

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) recently concluded successfully in Orlando, USA. As the “year-end flagship event” in hematology, ASH 2025 presented a series of landmark advances in the field of lymphoma, offering new directions for optimizing clinical practice.

Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a clonal proliferative disorder of mature B cells that predominantly affects older adults and is characterized by a distinctive immunophenotype. At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Skłodowska-Curie National Research Institute of Oncology presented the first results of the BRUIN CLL-313 study. This randomized phase III trial compared the efficacy and safety of the non-covalent BTK inhibitor pirtobrutinib with bendamustine plus rituximab (BR) in treatment-naïve patients with CLL/SLL. On-site, Oncology Frontier – Hematology Frontier invited Professor Jurczak to provide insights into the study background, design, and clinical implications, offering forward-looking guidance for clinical practice.

The 2025 Annual Meeting of the American Society of Hematology (ASH) was held from December 6–9 in Orlando, USA, drawing global attention as one of the most influential international conferences…

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for transfusion-dependent thalassemia (TDT). However, transplant outcomes are influenced by donor type, transplant-related complications, and patient-specific factors, leaving room…

From December 6 to 10, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. The meeting highlighted the latest advances in both clinical hematology and basic research, driving progress in the diagnosis and treatment of hematologic diseases as well as translational research.In this issue, we feature the research achievements of Professor Wang Hui’s team, covering cutting-edge technologies such as 16-color full-spectrum flow cytometry, a weighted cytokine scoring system, and other innovative approaches. These studies provide solid scientific evidence for early precise diagnosis, treatment response assessment, and timely clinical intervention, demonstrating the critical role of technological innovation in modern hematology. We warmly invite readers to engage in further discussion and exchange.